Catalysts for $ABBV
477 tracked
Mar 16, 2022
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jan 21, 2022
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 14, 2022
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 14, 2021
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Dec 2, 2021
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Nov 30, 2021
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Nov 30, 2021
approval
DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Nov 30, 2021
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Oct 22, 2021
approval
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Oct 4, 2021
approval
VENCLEXTA (VENETOCLAX) — FDA approval
venetoclax
→
Sep 28, 2021
approval
QULIPTA (ATOGEPANT) — FDA approval
atogepant
→
Sep 21, 2021
approval
ESCITALOPRAM OXALATE — FDA approval
AbbVie Inc.
→
Sep 8, 2021
approval
ESCITALOPRAM OXALATE — FDA approval
AbbVie Inc.
→
Sep 8, 2021
approval
ESCITALOPRAM OXALATE — FDA approval
AbbVie Inc.
→
Sep 8, 2021
approval
ESCITALOPRAM OXALATE — FDA approval
AbbVie Inc.
→
Aug 24, 2021
approval
LINZESS (LINACLOTIDE) — FDA approval
linaclotide
→
Aug 2, 2021
approval
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Apr 26, 2021
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 26, 2021
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Apr 12, 2021
approval
LINZESS (LINACLOTIDE) — FDA approval
linaclotide
→
Feb 24, 2021
approval
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 10, 2021
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Feb 10, 2021
approval
DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Feb 10, 2021
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Feb 1, 2021
approval
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Feb 1, 2021
approval
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Feb 1, 2021
approval
ORILISSA (ELAGOLIX SODIUM) — FDA approval
elagolix sodium
→
Dec 22, 2020
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Dec 22, 2020
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→